SCTX (Scribe Therapeutics) FCF Margin %: -339.10% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCTX Scribe Therapeutics Inc SCTX
8 GF Score
Price $22.00
View Full Analysis

What is Scribe Therapeutics FCF Margin %?

Scribe Therapeutics SCTX -13.40% 8 FCF Margin % is -339.10% as of Mar. 2026. GuruFocus rates SCTX with a GF Score™ of 8/100.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Scribe Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-7.57 Mil. Scribe Therapeutics's Revenue for the three months ended in Mar. 2026 was $2.23 Mil. Therefore, Scribe Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was -339.10%.

As of today, Scribe Therapeutics's current FCF Yield % is -320,800.00%.

The historical rank and industry rank for Scribe Therapeutics's FCF Margin % or its related term are showing as below:


SCTX's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -81.28
* Ranked among companies with meaningful FCF Margin % only.

Scribe Therapeutics FCF Margin % Related Terms

Scribe Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Scribe Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scribe Therapeutics FCF Margin % Chart

Scribe Therapeutics Annual Data
Trend Dec24 Dec25
FCF Margin %
-169.93 -90.84

Scribe Therapeutics Quarterly Data
Dec24 Mar25 Dec25 Mar26
FCF Margin % 0.00 -82.41 0.00 -339.10

SCTX vs : FCF Margin % Comparison

For the Biotechnology subindustry, Scribe Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scribe Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scribe Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Scribe Therapeutics's FCF Margin % falls into.


SCTX
8GF Score
Scribe Therapeutics Inc SCTX
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scribe Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Scribe Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-46.484/51.174
=-90.84 %

Scribe Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-7.572/2.233
=-339.10 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -339.10% mean?
Scribe Therapeutics (SCTX) has a FCF Margin % of -339.10% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Scribe Therapeutics and its competitors.
Is Scribe Therapeutics' FCF Margin % too high?
Scribe Therapeutics' current FCF Margin % is -339.10%. Overall, Scribe Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Scribe Therapeutics' FCF Margin % compare to ?
Scribe Therapeutics' FCF Margin % of -339.10% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Scribe Therapeutics and its competitors. Scribe Therapeutics's current FCF Margin % is -339.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scribe Therapeutics stock overvalued right now?
Scribe Therapeutics (SCTX) has a current FCF Margin % of -339.10%. The current FCF Margin % is -339.10%. Scribe Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Scribe Therapeutics (SCTX), the current FCF Margin % is -339.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scribe Therapeutics Business Description

Comparable Companies
Address 1150 Marina Village Parkway, Alameda, CA, USA, 94501
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
8GF Score

Get the complete analysis for SCTX

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.00
Price